| Excerpt | Reference |
|---|
| "Kawasaki disease is now the most common cause of acquired heart disease in America's children." | ( Lux, KM, 1991) |
| "Kawasaki disease is a multisystem disorder with varying clinical expression." | ( Kim, HM; Kim, JS; Lee, HY; Lim, BK; Park, MS; Yang, JS, 1991) |
| "Kawasaki disease is an immunologically mediated diffuse vasculitis of childhood of unknown etiology." | ( Barron, KS, 1991) |
| "Kawasaki disease is a mucocutaneous lymph node syndrome with important cardiovascular complications that usually afflicts young children." | ( Bégin, P; Genest, P; Laramée, P; Leclerc, G, 1986) |
| "Patients with Kawasaki disease are mostly in Japan, however, an increasing number of patients have recently been published in the foreign literatures, and this entity has become an important cause of heart disease in children." | ( Ichinose, E; Kato, H, 1983) |
| "Kawasaki Syndrome is a newly recognized clinical entity characterized by multisystem involvement." | ( Melish, ME, 1982) |
| "Kawasaki syndrome is a newly described, acute symptom complex of children that has a predictable clinical course." | ( Melish, ME, 1981) |
| "Kawasaki disease is now the leading cause of acquired heart disease in children in most developed countries." | ( De Inocencio, J; Hirsch, R; Shulman, ST, 1995) |
| "Kawasaki disease is an inflammatory disease of unknown etiology." | ( Neudorf, U, 1993) |
| "Kawasaki syndrome is an acute multisystem vasculitis of infancy and early childhood associated with high fever, mucocutaneous inflammation, and the development of coronary artery abnormalities." | ( Fulton, D; Leung, DY; Meissner, C; Schlievert, PM, 1995) |
| "Kawasaki disease is an acute inflammatory process of the arterial walls that results in panvasculitis in early childhood." | ( Dayanikli, F; Di Carli, MF; Morrow, WR; Muzik, O; Paridon, SM; Singh, TP, 1996) |
| "Kawasaki disease (mucocutaneous lymph node syndrome) is a disease of unknown aetiology that affects infants and children, with most patients having myocardial involvement." | ( Chang, JS; Kao, CH; Lee, JK; Shih, WJ; Tsai, CH, 1997) |
| "Kawasaki disease is known to cause a vasculitis of small and medium-sized vessels, with subsequent aneurysm formation." | ( Bradway, MW; Drezner, AD, 1997) |
| "Kawasaki disease is an acute systemic vasculitis of unknown cause first described in Japan in 1967." | ( Bradley, DJ; Glodé, MP, 1998) |
| "Kawasaki disease is a febrile disease of children notable for systemic vasculitis." | ( Furukawa, S; Hayashi, T; Ichiyama, T; Koga, M; Nishikawa, M; Tashiro, N, 1998) |
| "Kawasaki disease is an inflammatory disease of unknown cause that causes panvasculitis, including coronary arteritis." | ( Fujita, I; Hamasaki, Y; Ichimaru, T; Matsuo, M; Miyazaki, S; Tasaki, H; Tashiro, K; Zaitsu, M, 2000) |
| "Kawasaki disease is the leading cause of acquired heart disease in children in the developed world, with coronary artery aneurysms occurring in up to 25% of untreated cases." | ( Han, RK; McCrindle, BW; Newman, A; Silverman, ED; Sinclair, B; Taylor, GW; Walsh, P, 2000) |
| "Kawasaki disease is a systemic vasculitis that manifests itself in many ways." | ( Brenner, JL; Jadavji, T; Patton, D; Pinto, A; Trevenen, C, 2000) |
| "Kawasaki disease is the leading cause of acquired heart disease in childhood." | ( Fulton, DR; Newburger, JW, 2000) |
| "Kawasaki disease is an acute vasculitis of unknown cause that affects children under 5 years of age and in 20-25% of cases can cause coronary artery anomalies." | ( Barone, P; Betta, P; Distefano, G; Falsaperla, R; Marletta, M; Mattia, C; Sciacca, P; Tornambene, G, 2001) |
| "Kawasaki disease is a fever disease usually occurring in very young children." | ( Balcar-Boroń, A; Dylewska, K; Kojro-Wojcieszonek, A; Maćkowska, K; Masłowska, E, 2001) |
| "Kawasaki disease is an acute self-limited vasculitis of infancy and early hildhood that is now the leading cause of acquired heart disease in children in the United States and Japan." | ( Burns, JC, 2001) |
| "Kawasaki disease is a syndrome of unknown etiology affecting children below 5 years of age and is a leading cause of acquired heart disease in many developed countries." | ( Bhandari, B; Bhandari, H; Pendse, RN; Vats, AK, 2001) |
| "Kawasaki disease is a systemic vasculitis of unknown aetiology that has been reported worldwide since its initial description in Japanese children." | ( Minich, LL; Tani, LY; Williams, RV, 2001) |
| "Kawasaki disease is a childhood vasculitis of medium-sized vessels, affecting the coronary arteries in particular." | ( Achterhuis, A; Becker, AE; Biezeveld, M; Hack, CE; Kuijpers, TW; Kuipers, I; Lam, J; van der Wal, AC, 2003) |
| "Kawasaki disease is an acute, self-limited vasculitis of childhood characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy." | ( Fulton, DR; Newburger, JW, 2004) |
| "Kawasaki disease is an acute self-limited vasculitis of childhood that is characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy." | ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004) |
| "Kawasaki disease is an acute self-limited vasculitis of childhood that is characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy." | ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004) |
| "Kawasaki disease is an acute vasculitis of infancy and childhood." | ( Aronoff, SC; Wooditch, AC, 2005) |
| "Kawasaki disease is not rare in our region." | ( Amri, F; Belkadhi, A; Chemli, J; Essoussi, AS; Gueddiche, N; Harbi, A; Kchaou, H, 2005) |
| "Kawasaki disease is the leading cause of acquired heart disease in childhood." | ( Chang, FY; Chen, SJ; Hwang, B; Lee, PC; Lu, JH; Meng, CC, 2006) |
| "Kawasaki disease is a systemic necrotizing vasculitides concerning medium arteries and affecting predominantly young children." | ( Aboutara, M; Belaïda, A; Galempoix, JM; Kaeppler, E; Lanoux, P; Penalba, C, 2006) |
| "The occurrence of Kawasaki disease is unusual in adults." | ( Crespo, A; Menezes, L; Velez, AP, 2006) |
| "Kawasaki disease is the most common cause of acquired heart disease in children in developed countries." | ( Baumer, JH; Dua, JS; Gupta, A; Haines, LC; Love, SJ; Maconochie, I, 2006) |
| "Kawasaki disease is an acute febrile, systemic vasculitic syndrome of an unknown etiology that primarily occurs in children younger than five years of age." | ( Kim, DS, 2006) |
| "Kawasaki disease is a multi system disorder with varying clinical expressions." | ( Amin, R; Nabavizadeh, SH; Safari, M, 2006) |
| "Kawasaki Disease is a small-to-medium-vessel vasculitis that preferentially affects children." | ( Hansen, KE; Wolff, AE; Zakowski, L, 2007) |
| "A patient with Kawasaki disease is reported who had a medium-sized CAA prematurely occluded with thrombi during regression, resulting in myocardial ischemia." | ( Kwon, K; Sohn, S, 2008) |
| "Kawasaki disease is not uncommon in south India." | ( Ranjith, MS; Suresh, N; Varadarajan, VV, 2007) |
| "Kawasaki disease is an acute, self-limited vasculitis of childhood." | ( Kafetzis, DA; Pinna, GS; Skevaki, CL; Tselkas, OI, 2008) |
| "Kawasaki disease is one of the leading causes of acquired heart disease in children while its cause remains essentially unknown." | ( Kafetzis, DA; Pinna, GS; Skevaki, CL; Tselkas, OI, 2008) |
| "Refractory Kawasaki disease is difficult to treat and may require retreatment with intravenous immunoglobulins (IVIG), methylprednisolone or other immunological agents." | ( Prabhu, SS; Shah, I, 2009) |
| "Kawasaki disease is recognized as a leading cause of acquired heart disease in some Western countries." | ( Imbert, P; Miandrisoa, RM; Rakotomamonjy, SP; Rakotonirina, G; Rakotovao, DN; Ramanitrarivo, VL, 2008) |
| "Kawasaki disease is a systemic vasculitis occurring in children of all ages." | ( Farhang, S; Javadzadegan, H; Mehdizadeh Baghbani, J, 2009) |
| "Kawasaki disease is an acute febrile illness of infants and children with unknown etiology." | ( Onouchi, Y, 2010) |
| "Kawasaki disease is a well-known disease in young children." | ( Bonello, B; Bosdure, E; Bresson, V; Chabrol, B; Dubus, JC; Rousset-Rouvière, C; Serratrice, J, 2011) |
| "Kawasaki disease is a systemic vasculitis, mainly encountered in children." | ( Attilakos, A; Fretzayas, A; Karpathios, T; Moustaki, M; Papadopoulou, A; Sharifi, F; Yiallouros, P, 2012) |
| "Kawasaki disease is a systemic vasculitis and the leading cause of acquired heart disease in North American and Japanese children." | ( Scuccimarri, R, 2012) |
| "Kawasaki disease is far more frequent in children than in adults." | ( Huang, F; Sun, L; Yan, Z; Yu, X; Zhou, Y, 2012) |
| "Kawasaki disease is an acute febrile vasculitis of childhood that is associated with elevated production of inflammatory cytokines, causing damage to the coronary arteries." | ( Hasegawa, S; Hirano, R; Ichiyama, T; Kittaka, S; Kudo, K; Suzuki, Y; Wakiguchi, H, 2012) |
| "Kawasaki disease is an important differential diagnosis when evaluating prolonged fever in childhood." | ( Clausen, H; Giardini, A; Howarth, C, 2012) |
| "Kawasaki disease is an acute, self-limited vasculitis of childhood that can result in structural damage to the coronary arteries." | ( Akers, JC; Burns, JC; Chen, C; Kanegaye, JT; Kim, J; Lau, HD; Ohno-Machado, L; Shimizu, C; Stepanowsky, P; Tremoulet, A; Trinh, C, 2013) |
| "Kawasaki disease is a multi-system vasculitis which usually occurs in children under 5 years of age." | ( Barone, P; Di Stefano, V; Gravina, G; La Rosa, M; Leonardi, S; Parisi, GF; Sciacca, P, 2013) |
| "Kawasaki disease is an acute multisystemic vasculitis occurring predominantly in infants and young children and rarely in adolescents and adults." | ( Jankauskas, A; Jurkienė, N; Kėvalas, R; Kudzytė, J; Labanauskas, L; Rakauskienė, V; Šileikienė, R, 2013) |
| "Kawasaki disease is an acute febrile vasculitis of childhood." | ( Kundu, R; Mukherjee, D; Niyogi, P; Pal, P, 2014) |
| "Kawasaki disease is an acute systemic vasculitis of childhood." | ( Kajosaari, L; Klockars, T; Nieminen, T; Puhakka, L; Saat, R; Salo, E, 2014) |
| "Kawasaki disease is an acute, systemic vasculitis that predominantly affects patients younger than five years." | ( Fargo, M; Grogan, S; Saguil, A, 2015) |
| "Kawasaki disease is an acute necrotising vasculitis of the medium- and small-sized vessels, occurring mainly in Japanese and Korean babies and children, aged 6 months to 5 years." | ( Kontopoulos, DG; Kontopoulou, T; Mousoulis, GP; Vaidakis, E, 2015) |
| "Kawasaki disease is rarely complicated by cranial nerve VII palsy." | ( Stowe, RC, 2015) |
| "Kawasaki disease is a small-to-medium-vessel vasculitis of unknown origin that predominantly affects children, although the disease can occur in adults." | ( Garrido-García, LM; López-Amézquita, M; Villaverde-Rosas, R, 2016) |
| "Diagnosis of Kawasaki disease is based on a constellation of clinical findings which have a typical temporal sequence." | ( Kawasaki, T; Singh, S, 2016) |
| "Kawasaki disease is an acute, self-limited vasculitis of unknown etiology that occurs predominantly in infants and children." | ( Burns, JC; Newburger, JW; Takahashi, M, 2016) |
| "Kawasaki disease is an acute febrile systemic vasculitis that predominantly occurs in children below five years of age." | ( Agarwal, S; Agrawal, DK, 2017) |
| "Kawasaki disease is a common systemic vasculitis that leads to coronary artery lesions." | ( Aiba, Y; Hayashi, K; Kato, M; Koga, Y; Matsuda, S; Mochizuki, H; Nakamura, H; Niimura, F; Sekine, K; Suganuma, E; Takahashi, O; Ukawa, T, 2017) |
| "Kawasaki disease is an acute multisystem childhood vasculitis with a predilection for the coronary arteries." | ( Dhanrajani, A; Yeung, RSM, 2017) |
| "Kawasaki disease is a necrotizing vasculitis featuring fever, erythema, conjunctivitis, and lymphadenopathy." | ( Gao, Y; Lu, F; Wang, X; Zhang, M; Zhang, Y, 2018) |
| "Kawasaki disease is a kind of systemic vasculitis that mainly damages moderate and small-sized blood vessels, and is a leading cause of coronary artery lesions (CAL)." | ( Bao, L; Che, D; Deng, Q; Fang, Z; Gu, X; Li, J; Li, M; Li, W; Lin, S; Liu, T; Liu, Y; Long, H; Pi, L; Zhang, L; Zhang, Y, 2018) |
| "Kawasaki disease is a common childhood vasculitis which may result in cardiovascular morbidity if not adequately treated." | ( Lakhani, N; Noorani, M, 2018) |
| "Kawasaki disease is an autoimmune disease that commonly affects children below the age of 5 years." | ( Ng, SH; Roshan, S, 2018) |
| "In the early stage, Kawasaki disease is often manifested by uncommon symptoms, such as pyuria, meningitis, shock, and retropharyngeal or parapharyngeal abscess, which may delay diagnosis and treatment." | ( Li, Y; Qiao, H; Yang, Q; Yu, X, 2019) |
| "Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA)." | ( Cimaz, R; Giani, T; Marrani, E; Tirelli, F, 2020) |
| "Kawasaki disease is an acute, febrile vasculitis of childhood that affects medium-sized arteries, predominantly the coronary arteries." | ( Arslanoglu Aydin, E; Aydin, O; Bilginer, Y; Demir, S; Ozen, S, 2019) |
| "Kawasaki disease is an acute vasculitis syndrome that typically occurs in children aged 1 to 4 years." | ( Adams, L; Levasseur, K; Patel, F; Rosario, JM, 2019) |
| "Kawasaki disease is an acute systemic febrile vasculitis of medium and small arteries, most often occurring in children under age 5 years." | ( Galuppo, J; Kowker, A; Nicholas, J; Rolfs, J; Schmidt, E, 2020) |
| "Indeed, Kawasaki disease is induced by overreaction of innate cells following exposition to various viruses, including herpes viruses which trigger STING." | ( Berthelot, JM; Drouet, L; Lioté, F, 2020) |
| "Kawasaki disease is a common rheumatological disorder in children at our center with diverse clinical presentations." | ( Bora, S; Hoque, RA; Iqbal, F; Kom, LB; Narayan Dev, C; Sharma, D, 2021) |
| "Kawasaki disease is an autoimmune disease characterized by systemic vasculitis of unknown aetiology and most commonly occurs in children under 5 years old." | ( Huang, Y; Wang, L; Weng, R; Wu, Q; Xu, Y; Yang, J, 2021) |
| "Kawasaki disease is a kind of self-limited systemic vasculitis involving middle and small arteries, which usually occurs in children under 5 years old." | ( Huang, Y; Wang, L; Weng, R; Wu, Q; Yang, J; Yang, Z, 2021) |
| "Kawasaki disease is a common vasculitis of unknown etiology that occurs mainly in preschool children." | ( Noorani, M; Osman, RS; Salum, HM, 2021) |
| "Kawasaki disease is an idiopathic medium-sized vasculitis that occurs primarily in infants and children younger than 5 years of age." | ( Abdulrahman, A; Al Qahtani, F; Aldajani, A; Alhaji, M; Alshammasi, W; Bargawi, A, 2022) |
| "Kawasaki disease is a febrile illness which can lead to significant coronary artery lesions." | ( Boulos Ksontini, T; Bressieux-Degueldre, S; Di Bernardo, S; Gradoux, E; Mivelaz, Y; Prsa, M; Sekarski, N, 2022) |
| "Kawasaki disease is an acute febrile condition in children." | ( Dayasiri, K; Ragunathan, IR; Thadchanamoorthy, V, 2023) |
| "Kawasaki disease is one of the important differential diagnoses of protracted fever of unknown origin in very young children." | ( Dayasiri, K; Ragunathan, IR; Thadchanamoorthy, V, 2023) |
| "Kawasaki disease is an acute, febrile disease that is not typically fatal if treated and affects infants and children more commonly." | ( Aleti, S; Alsir, O; Amir, O; Elhag, M; Gadam, S; Gupta, K; Inban, P; Mahmoud, M; Prajjwal, P; Sunasra, RR, 2023) |
| "Kawasaki disease is an acute, febrile disease that is not typically fatal if treated and affects infants and children more commonly." | ( Aleti, S; Alsir, O; Amir, O; Elhag, M; Gadam, S; Gupta, K; Inban, P; Mahmoud, M; Prajjwal, P; Sunasra, RR, 2023) |
| "Kawasaki disease is an acute, febrile disease that is not typically fatal if treated and affects infants and children more commonly." | ( Aleti, S; Alsir, O; Amir, O; Elhag, M; Gadam, S; Gupta, K; Inban, P; Mahmoud, M; Prajjwal, P; Sunasra, RR, 2023) |
| "Kawasaki disease is an acute, febrile disease that is not typically fatal if treated and affects infants and children more commonly." | ( Aleti, S; Alsir, O; Amir, O; Elhag, M; Gadam, S; Gupta, K; Inban, P; Mahmoud, M; Prajjwal, P; Sunasra, RR, 2023) |
| "Kawasaki disease is a systemic vasculitis that affects small and medium-sized vessels, primarily the coronary arteries." | ( Arellano-Valdez, A; Bonal-Pérez, MA; Marriaga-Núñez, B; Montaño-Durón, JG; Paz, JPA; Solórzano-Santos, F, 2023) |
| Excerpt | Reference |
|---|
| "Ninety-two patients with Kawasaki disease were treated with five different types of drug therapy: a steroid preparation (prednisolone), aspirin, an antibiotic, a combination of steroid plus aspirin, and a combination of steroid plus warfarin." | ( Kato, H; Koike, S; Yokoyama, T, 1979) |
| "To determine the role of cytokines in Kawasaki disease, serial measurements of serum cytokine levels were done in 60 patients treated solely with aspirin." | ( Chiang, B; Hwang, B; Lin, CC; Lin, CY, 1992) |
| "This is a report on one case of Kawasaki disease which during its clinical course developed facial nerve palsy and spontaneous recovery without specific treatment." | ( Kim, HM; Kim, JS; Lee, HY; Lim, BK; Park, MS; Yang, JS, 1991) |
| "Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial." | ( Akagi, T; Inoue, O; Kato, H; Sato, N, 1991) |
| "Aspirin is the basic treatment for Kawasaki disease, however its optimal dose is controversial." | ( Akagi, T; Inoue, O; Kato, H; Sato, N, 1990) |
| "Treatment guidelines for Kawasaki disease are being refined." | ( Edwards, DL; Nakashima, L, 1990) |
| "To investigate the effect of Kawasaki syndrome on myocardial function, as well as the influence of high-dose intravenous gamma-globulin therapy on resolution of functional abnormalities, we studied 98 patients with Kawasaki syndrome during five time intervals from onset of illness: 1) 10 days or less, 2) 11-31 days, 3) 1-3 months, 4) 3-12 months, and 5) 1-3 years." | ( Beiser, AS; Burns, JC; Colan, SD; Newburger, JW; Parness, IA; Sanders, SP, 1989) |
| "The prediction of the severity of Kawasaki disease in terms of coronary artery disease is important for the evaluation of prognosis as well as for making decisions on an appropriate form of treatment." | ( Nakano, H, 1987) |
| "The patient was diagnosed as having Kawasaki disease, and treatment with aspirin was started." | ( Haines, JD, 1987) |
| "Twenty-one patients with acute state Kawasaki disease (15 boys, 6 girls; age range, 1-8 years) had equilibrium multigated blood pool ventriculography (EMBPV) before treatment." | ( Chen, YC; Hsieh, KS; Kao, CH; Wang, SJ; Yeh, SH, 1994) |
| "Among 291 cases of Kawasaki syndrome diagnosed during the period of 1987 to 1991 without coronary abnormalities within 10 days of the onset of illness, 128 were treated with IVGG and aspirin and were compared with 163 treated with aspirin alone." | ( Chen, MR; Hsu, CH; Hung, HY; Hwang, FY; Kao, HA, 1993) |
| "For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to IVIG-HD therapy and 14 cases of coronary artery dilation were thereby prevented." | ( Gafni, A; Klassen, TP; Rowe, PC, 1993) |
| "Treatment with IVIG-HD for Kawasaki syndrome is preferred because it results in both lower costs and lower rates of coronary artery dilation." | ( Gafni, A; Klassen, TP; Rowe, PC, 1993) |
| "We describe four children with Kawasaki disease resistant to treatment with intravenously administered immune globulin who were treated with high doses of methylprednisolone." | ( Baker, A; Newburger, JW; Sundel, RP; Wright, DA, 1996) |
| "A 4-month-old girl with Kawasaki disease, large coronary artery aneurysms, and coronary thrombi was treated with standard therapy followed by abciximab, a platelet glycoprotein IIb/IIIa antagonist, in addition to standard heparin and warfarin sodium anticoagulation and low-dose aspirin." | ( Etheridge, SP; Minich, LL; Revenaugh, JR; Tani, LY, 1998) |
| "We describe a boy with Kawasaki disease (KD) whose clinical course was marked by a rapid improvement upon treatment with intravenous immunoglobulin (IVIG) and oral aspirin, which - within 14 days - was followed by the development of a large pericardial effusion with symptoms of impending cardiac tamponade as part of a polyserositis syndrome (pleural effusions, ascites)." | ( Dahlem, PG; Kuijpers, TW; Lam, J; von Rosenstiel, IA, 1999) |
| "Children with Kawasaki disease (n = 82), treated with intravenous immune globulin (IVIG) at a high dose, were classified as IVIG-responsive (defervescence within 5 days of starting IVIG, n = 69) or IVIG-non-responsive (consistent fever over a 6-day period since starting IVIG, n = 13)." | ( Fukunishi, M; Hamana, K; Hara, J; Kikkawa, M; Matsumoto, Y; Matsuzaki, K; Onodera, T, 2000) |
| "In five children with Kawasaki disease we measured serum IL-6 before and after IVIG and assessed the clinical response to IVIG therapy." | ( Bussel, J; Friedman, D; Gupta, M; Johann-Liang, R; Noel, GJ; Schaefer, M, 2001) |
| "Such a treatment of Kawasaki disease prevents the coronary vessel lesions." | ( Balcar-Boroń, A; Dylewska, K; Kojro-Wojcieszonek, A; Maćkowska, K; Masłowska, E, 2001) |
| "We report an uncommon case of Kawasaki disease in 10 months old male child with the analysis of its natural history, etiopathology, treatment and prognosis of the disease." | ( Saraf, S; Singh, RK, 2001) |
| "A subgroup of patients with Kawasaki disease (KD) did not respond to intravenous immune globulin (IVIG) therapy." | ( Chiu, CH; Hung, JJ, 2004) |
| "Long-term management of patients with Kawasaki disease is tailored to the degree of coronary involvement; recommendations regarding antiplatelet and anticoagulant therapy, physical activity, follow-up assessment, and the appropriate diagnostic procedures to evaluate cardiac disease are classified according to risk strata." | ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004) |
| "Long-term management of patients with Kawasaki disease is tailored to the degree of coronary involvement; recommendations regarding antiplatelet and anticoagulant therapy, physical activity, follow-up assessment, and the appropriate diagnostic procedures to evaluate cardiac disease are classified according to risk strata." | ( Baddour, LM; Baltimore, RS; Bolger, AF; Burns, JC; Falace, DA; Ferrieri, P; Gerber, MA; Gewitz, MH; Levison, ME; Newburger, JW; Pallasch, TJ; Shulman, ST; Takahashi, M; Tani, LY; Taubert, KA; Wilson, WR, 2004) |
| "Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose)." | ( Kawamura, Y; Nakatani, K; Takeshita, S; Tokutomi, T; Tsujimoto, H, 2005) |
| "Standard treatment of Kawasaki disease was administered (immunoglobulins, acetylsalicylic acid) and orciprenalin due to described cardiac block." | ( Berdej-Szczot, E; Giec-Fuglewicz, G; Gołba, E; Kohut, J; Smoleńska-Petelenz, J; Szydłowski, L, 2006) |
| "Treatment of acute Kawasaki disease with intravenous immune globulin and aspirin reduces the risk of coronary-artery abnormalities and systemic inflammation, but despite intravenous immune globulin therapy, coronary-artery abnormalities develop in some children." | ( Atz, AM; Baker, AL; Colan, SD; Gersony, W; Klein, GL; Li, JS; McCrindle, BW; Minich, LL; Mitchell, PD; Newburger, JW; Sleeper, LA; Sundel, RP; Takahashi, M; Vetter, VL, 2007) |
| "Infants with incomplete and atypical Kawasaki disease are prone to intravenous immunoglobulin treatment failure and are at risk for the development of coronary artery aneurysms." | ( O'connor, MJ; Saulsbury, FT, 2007) |
| "We enrolled 164 patients with Kawasaki disease who were treated with a single dose of IVIG (2 g/kg) and aspirin (30 mg/kg per day)." | ( Ando, H; Bando, Y; Furukawa, S; Ishii, M; Kaida, M; Kaneko, T; Kimura, S; Minoura, K; Nakahata, Y; Ogata, S; Ogihara, Y; Yokota, Y, 2009) |
| "Refractory Kawasaki disease is difficult to treat and may require retreatment with intravenous immunoglobulins (IVIG), methylprednisolone or other immunological agents." | ( Prabhu, SS; Shah, I, 2009) |
| "Standard treatment of acute Kawasaki disease involves giving 2 grams per kilogram of immunoglobulin intravenously along with aspirin." | ( Ichihashi, K; Momoi, M; Shiraishi, H, 2009) |
| "All patients with Kawasaki disease and large CAAs (diameter >5 mm or Z score >10) treated from 1986 to 2007 were identified and divided into 2 groups." | ( McCandless, RT; Minich, LL; Tani, LY; Williams, RV, 2010) |
| "Corticosteroid administration in Kawasaki disease (KD) is controversial but accepted as treatment for patients who do not respond to initial treatment." | ( Manlhiot, C; McCrindle, BW; Millar, K; Somji, Z; Yeung, RS, 2012) |
| "The current recommended therapy for Kawasaki disease (KD) is the combination of intravenous immunoglobulin (IVIG) and aspirin." | ( Cao, L; Jia, HL; Lv, HT; Shen, YP; Sun, L; Yan, WH; Zhang, JM; Zhu, BH, 2012) |
| "The diagnosis and treatment of Kawasaki disease are discussed." | ( Floriańczyk, T; Gołąbek-Dylewska, M; Werner, B, 2011) |
| "The diagnostic challenge of Kawasaki disease and its implications for coronary artery outcomes are discussed, as are the recommended treatment, ongoing treatment controversies, concerns associated with treatment resistance, and the importance of ongoing follow up." | ( Scuccimarri, R, 2012) |
| "Acute Kawasaki disease (KD) is treated with high-dose intravenous immunoglobulin (IVIG), which is proven to decrease the incidence of coronary artery aneurysms from 25% to less than 5%." | ( Burgner, D; Kuijpers, TW; Kuipers, IM; Tacke, CE, 2012) |
| "Although Kawasaki disease (KD) is now being increasingly reported from India, the vast majority of children with KD are still not being diagnosed and treated." | ( Aulakh, R; Kawasaki, T; Singh, S, 2014) |
| "At elderly age, Kawasaki disease may remain unrecognized with a subsequent delay in appropriate therapy and an increased risk of coronary artery aneurysms." | ( Jankauskas, A; Jurkienė, N; Kėvalas, R; Kudzytė, J; Labanauskas, L; Rakauskienė, V; Šileikienė, R, 2013) |
| "4-year-old boy with Kawasaki Disease treated with intravenous immunoglobulins." | ( Kundu, R; Mukherjee, D; Niyogi, P; Pal, P, 2014) |
| "Prednisolone therapy for acute phase Kawasaki disease had been considered to be controversial for several decades." | ( Arakawa, H; Kobayashi, T, 2014) |
| "Untreated Kawasaki disease may lead to the formation of coronary artery aneurysms and sudden cardiac death in children." | ( Kharbanda, A; Seaton, KK, 2015) |
| "We present a case of Kawasaki Disease (KD) that was refractory to plasma exchange (PE), but which finally responded to concurrent intravenous methylprednisolone pulse (IVMP) and PE treatment." | ( Matsui, M; Matsushita, T; Okuma, Y; Sato, N; Shichino, H; Uryu, H; Yamanaka, J, 2015) |
| "We report a 10-month-old infant with Kawasaki disease who was treated with high-dose IVIg and developed severe HA." | ( Inaba, A; Kurano, T; Nakayama, H; Soebijanto, K; Sonoda, M; Tocan, V, 2017) |
| "Standard first-line therapy for Kawasaki disease (KD) consists of intravenous immunoglobulin (IVIG) and aspirin." | ( Shulman, ST, 2017) |
| "We included patients diagnosed with Kawasaki disease according to the Japanese diagnostic criteria, and excluded those who were treated at other hospitals before being transferred to a participating hospital." | ( Chiga, M; Hori, N; Kaneko, T; Komiyama, O; Matsushima, T; Misawa, M; Miura, M; Miyata, K; Morikawa, Y; Nakazawa, M; Obonai, T; Sakakibara, H; Takahashi, T; Tamame, T; Tsuchihashi, T; Yamagishi, H; Yamashita, Y, 2018) |
| "immunoglobulin (IVIG) treatment for Kawasaki disease (KD)." | ( Hashimoto, I, 2019) |
| "In the early stage, Kawasaki disease is often manifested by uncommon symptoms, such as pyuria, meningitis, shock, and retropharyngeal or parapharyngeal abscess, which may delay diagnosis and treatment." | ( Li, Y; Qiao, H; Yang, Q; Yu, X, 2019) |
| "We describe adult-onset Kawasaki disease (KD) and review clinical manifestations and treatment guidelines." | ( Dupuy, EO; Kang, Y; Knowles, BC; Sarantopoulos, GP; Vecerek, N; Worswick, S, 2019) |
| "Studies related to aspirin therapy for Kawasaki disease were selected by searching the databases of Medline (PubMed), Embase and the Cochrane Library before March 2019." | ( Bao, Y; Bie, S; Du, X; Jia, X; Jiang, M; Li, X, 2020) |
| "What is Known: • For treatments of Kawasaki disease at any age in the acute phase, 2-g/kg single-dose intravenous immunoglobulin and aspirin have been the most recommended to reduce fever early and prevent complications of coronary artery abnormalities." | ( Fushimi, K; Hata, T; Matsui, H; Michihata, N; Suzuki, T; Yasunaga, H; Yoshikawa, T, 2020) |
| "Early diagnosis of Kawasaki disease (KD) is critical to allow prompt initiation of treatment and avoid cardiac complications." | ( Burns, JC; Piram, M, 2021) |
| "What is Known: • For treatments of Kawasaki Disease in acute phase, intravenous immunoglobulin have been the most recommended to reduce fever early and prevent complications of coronary artery abnormalities." | ( Aso, S; Fushimi, K; Matsui, H; Michihata, N; Saito, K; Suzuki, T; Yasunaga, H; Yoshikawa, T, 2021) |
| "Since the epidemiology of Kawasaki disease in Switzerland is unknown, we conducted a national prospective data collection between 2013 and 2017 to describe its incidence, diagnosis, and treatment." | ( Boulos Ksontini, T; Bressieux-Degueldre, S; Di Bernardo, S; Gradoux, E; Mivelaz, Y; Prsa, M; Sekarski, N, 2022) |
| "As a mainstay treatment for Kawasaki disease, aspirin may cause liver injury." | ( Fu, S; Gao, L; Geng, Z; Gong, F; Wang, H; Wang, W; Wang, Y; Xie, C; Xu, Z; Zhang, Y; Zhou, S, 2023) |